



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: C07K 7/08, C12N 15/31, C07K 16/12, A61K 38/10, 39/04, C07K 14/35	A1	(11) International Publication Number: WO 00/27870 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/IL99/00595 (22) International Filing Date: 4 November 1999 (04.11.99) (30) Priority Data: 60/107,213 5 November 1998 (05.11.98) US (71) Applicant (for all designated States except US): HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. [IL/IL]; P.O. Box 12000, 91120 Jerusalem (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): NAPARSTEK, Yankov [IL/IL]; Davidson Street 17, 91120 Jerusalem (IL). UL- MANSKY, Rina [IL/IL]; Narkiss Street 19, 90805 Jerusalem (IL). KASHI, Yochezekel [IL/IL]; Maneh-Hill Street 24, 34364 Haifa (IL). (74) Agents: LUZZATTO, Kfir et al.; Luzzatto & Luzzatto, P.O. Box 5352, 84152 Beer-Sheva (IL).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: NOVEL AMINO ACID SEQUENCES, DNA ENCODING THE AMINO ACID SEQUENCES, ANTIBODIES DIRECTED AGAINST SUCH SEQUENCES AND THE DIFFERENT USES THEREOF		
(57) Abstract The invention is directed to a peptide comprising the amino acid sequence substantially as denoted by SEQ ID NO. 1 and biologically functional homologues and derivatives thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL AMINO ACID SEQUENCES, DNA ENCODING
THE AMINO ACID SEQUENCES, ANTIBODIES
DIRECTED AGAINST SUCH SEQUENCES AND THE
DIFFERENT USES THEREOF

Field of the Invention

The present invention relates to various peptides, homologous to regions of heat shock protein (HSP), to DNA sequences encoding such peptides, to DNA constructs comprising the DNA sequences, to antibodies directed against peptides of the invention. The invention also relates to active vaccines comprising a peptide, a DNA sequence or a DNA construct of the invention, and to a passive immunization composition comprising an antibody of the invention.

Background of the Invention

Throughout this application, various publications are referred to by Arabic numerals in parentheses. These publications are incorporated herein in their entireties and constitute part of the description.

Adjuvant Arthritis (AA) is an experimental model of autoimmune arthritis which can be induced in susceptible strains of rats such as inbred Lewis or Wistar strains upon vaccination with heat-killed *Mycobacterium tuberculosis* (MT) in complete Freund's Adjuvant (CFA) [1-3]. The disease cannot be induced in resistant strains of rats (e.g., Brown-Norway; Fisher [5, 6], and Lewis rats develop resistance to re-induction of the disease after recovery from arthritis.

The inventors have previously shown that resistance to AA can be transferred to a susceptible strain of rats by intravenous infusion of immunoglobulins from the resistant strains, and that resistance is

associated with the presence of antibodies against the 65kD MT heat shock protein (HSP 65) [4].

Heat shock proteins are a family of highly conserved proteins. There is ~50% amino acid identity between the Mycobacterial HSP 65 and the mammalian HSP 60 [21]. The role of the 65kD heat shock protein (HSP 65) of MT in the pathogenesis of autoimmune arthritis, both in experimental animals [7, 8] as well as in humans [9-11], has been investigated intensively in the past several years. For example, Barker *et al.* [32] describe the suppression of arthritogenic immune responses in mice given HSP65 and pristane. The antigen used to elicit the response was full-length HSP65, and no attempt was made to investigate the effect of specific sub-domains or peptides deriving from this protein.

AA can be passively transferred by a T-cell clone reactive to residues 180-188 of the MT HSP 65, and in patients suffering from rheumatoid arthritis (RA), an association between T-cell responses to HSP 65 and early stages of joint inflammation has been found [7, 12-14]. Paradoxically, pre-immunization with the mycobacterial HSP 65 leads to resistance to induction of the disease by MT, and this protective effect is believed to be mediated by T cells specific for HSP 65 [7, 15-16]. Likewise, although arthritic rats develop vigorous T cell responses to self-HSP and to peptide 180-188 of the MT HSP, neither of these is arthritogenic when injected to arthritis-susceptible rats [15, 17]. These results and other suggest that HSP may contain epitopes that are disease-related and other epitopes that confer resistance [5, 19, 20]. Both the pathogenic immune response as well as the protective effect were attributed to anti-HSP T-cells. The following Examples illustrate the fine epitope specificity of the anti-HSP antibodies of arthritis-susceptible and resistant rats.

In addition, the inventors have found that naive Lewis rats lack antibodies to certain epitopes of the mycobacterial HSP 65 which are found naturally in young BN and old naive Lewis rats, and that are acquired by young Lewis rats after recovery from the disease. Analysis of the primary and tertiary structure of the whole MT HSP 65kD molecule indicated that these "protective" epitopes are potential B-cell epitopes with a non-conserved amino acid sequences that are found on the outer surface of the molecule.

Pre-immunization of Lewis rats with one of the "protective" epitopes prior to induction of the disease induced antibodies against the whole molecule as well as resistance to disease induction. This peptide corresponds also to the self-HSP 60 epitope to which antibodies were found in the arthritis - resistant rats, but not in the arthritis-susceptible naive Lewis rats.

Summary of the Invention

The present invention relates to a peptide comprising the amino acid sequence substantially as denoted by SED ID No. 1 and biologically functional homologues and derivatives thereof.

More particularly, the invention relates to a peptide having the amino acid sequence substantially as denoted by SED ID No. 2 and biologically functional homologues and derivatives thereof and to a peptide having the amino acid sequence substantially as denoted by SED ID No. 3 and biologically functional homologues and derivatives thereof.

In addition, the invention relates to a peptide comprising the amino acid sequence substantially as denoted by SED ID No. 4 and biologically functional homologues and derivatives thereof.

The peptides of the invention can be synthetic peptides and chemically modified peptides.

The peptides of the invention are capable of conferring immunity against autoimmune and/or inflammatory disorders.

In a further aspect, the invention relates to a nucleic acid sequence encoding a peptide of the invention and to DNA constructs comprising the same.

In yet a further aspect, the invention relates to vaccines comprising as active ingredient an effective vaccinating amount of at least one peptide of the invention, or a nucleic acid according to the invention. The vaccines of the invention are particularly useful in conferring immunity against autoimmune or inflammatory disorders.

Still further, the invention relates to antibodies directed against the peptides of the invention and to compositions comprising them. The compositions of the invention are particularly useful for the passive vaccination against autoimmune or inflammatory disorders.

Description of the Figures

Figure 1 *Amino acid comparison of three HSP 60 sequences*

Mycobacterium Tuberculosis, rat HSP 60 and human HSP 60 (sequences P06806, P19227 and P10809, corresponding to SEQ ID: Nos. 6, 7 and 8 respectively), were compared with pileup program from GCG-Wisconsin Package v9.0. The conserved regions are indicated (consensus). Bold, underlined residues represent the preferred peptides.

Figure 2 *Three dimensional structure of the E. coli GroEL-GroES complex*

The GroES heptameric ring is shown in dark gray. The two GroEL heptameric rings are shown in light gray. Peptides

6-7 (amino acids 31-52) and 31 (amino acids 181-197) are also indicated.

Figures 3a-3b *The location of peptides 6, 7 and 31 in the HSP 65 monomer*

The location of peptides 6, 7 and 31 in the HSP 65 monomer is indicated in a secondary structure configuration (Fig. 3a) and in the space filling mode (Fig. 3b).

Figure 4 *Vaccination with HSP peptides*

Vaccination against AA with HSP peptides 6, 7 and R5 is shown. PBS was employed as a control.

Figure 5 *The protecting motif within peptides 6, 7 and R5*

The common motif within peptides 6, 7 and R5, V--E--WG-P is shown.

Figure 6 *Restriction map of pTARGET*

Restriction map of the plasmid pTARGET is shown.

Detailed Description of the Invention

The present invention relates to peptides comprising the amino acid sequence substantially as denoted by SEQ ID:No. 1, and biologically functional homologues and derivatives thereof.

Preferably, the peptide according to the first embodiment of the invention has the amino acid sequence substantially as denoted by SEQ ID:No. 2 or the amino acid sequence substantially as denoted by SEQ ID:No. 3.

The invention further relates to a peptide comprising the amino acid sequence substantially as denoted by SEQ ID:No. 4 and biologically functional homologues and derivatives thereof.

The invention also relates to a nucleic acid sequence which encodes a peptide according to the invention.

More particularly, the invention relates to a DNA sequence comprising the nucleic acid sequence substantially as denoted by SEQ ID No. 5, and biologically functional derivatives thereof. This nucleic acid sequence encodes a peptide having the sequence substantially as denoted by SEQ ID No. 4.

The amino acid and nucleic acid sequences are presented in Table 1.

Table 1

SEQ No	ID	Peptide No.	Amino Acid or Nucleic Acid Sequence
1			GPKGRNVVLEKKWGAPTITNDG
2		6	GPKGRNVVLEKKWGAP
3		7	VVLEKKWGAPTITNDG
4		R5	TVIIEQSWGSPKVTKDGVTV
5			GCCGCCATGGGACCAAAGGGACGCAACGTGG TACTAGAGAAGAAATGGGGCGCGCCGTAGCT CGAGA

By the term "biologically functional homologues and derivatives" is meant any variations, including deletion, substitution and/or insertion of an amino acid residue in the amino acid sequences or a nucleic acid in the nucleic acid sequences of the invention which would not alter the biological activity of the peptides, or peptides encoded by the nucleic acid sequences, against autoimmune diseases. Thus, this term is to be taken to mean peptides with similar structure, peptides or their derivatives that are recognized by the protective antibodies and/or peptides or their derivatives that can induce protective antibodies upon immunization.

The invention further relates to DNA constructs comprising the nucleic acid sequence of the invention or functional homologues and derivatives thereof. The constructs of the invention may further comprise additional elements such as promoters, regulatory and control elements, translation, expression and other signals, operably linked to the nucleic acid sequence of the invention.

The invention also relates to a vaccine comprising as active ingredient an effective vaccinating amount of at least one peptide of the invention. The vaccines of the invention are particularly intended to confer immunity against inflammatory and autoimmune diseases, for example, rheumatoid arthritis or adjuvant arthritis.

By the term "effective vaccinating amount" is meant an amount sufficient to stimulate the immune system, directly or indirectly, and confer immunity against inflammatory and autoimmune diseases. Such effective amount is determined the severity of the disease, age, sex and weight of the patient, as well as the patient's general condition, and by other considerations known to the attending physician. Preferred doses, per injection, may be 0.02-2mg/Kg body weight.

The vaccines of the present invention may alternatively comprise as the active ingredient at least one nucleic acid sequence according to the invention.

The vaccines according to the invention may optionally further comprise pharmaceutically acceptable carriers, diluents additives, excipients and adjuvants. By the terms "pharmaceutically acceptable carriers, diluents additives, excipients and adjuvants" is meant any inert, non-toxic material that may assist in the efficient delivery of the active ingredient.

The term "antibody" as used in connection with the present invention refers to both polyclonal and monoclonal antibodies. Polyclonal antibodies may be generated in rabbits, chicken, mice, rats, sheep, or similar mammals. The generation of polyclonal antibodies against peptides is described in the above-noted Current Protocols in Immunology, Wiley and Sons Inc. Chapter 9.

Monoclonal antibodies may be prepared from B cells taken from the spleen or lymph nodes of immunized animals, in particular rats or mice, by fusion with immortalized B cells under conditions which favor the growth of hybrid cells. For fusion of murine B cells, the cell line Ag-8 is preferred.

The technique of generating monoclonal antibodies is described in many articles and textbooks, such as the above-noted Chapter 2 of Current Protocols in Immunology. Chapter 9 therein describes the immunization of laboratory animals with peptides. Spleen or lymph node cells of these animals may be used in the same way as spleen or lymph node cells of protein-immunized animals, for the generation of monoclonal antibodies as described in chapter 2 therein.

The term "antibody" is also meant to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody.

An antibody is said to be "directed against" a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody. Epitopes or "antigenic determinants" usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics.

An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An

antigen may have one or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

The antibodies of the invention may be provided in the form of compositions for use in passive immunization. While such compositions are generally administered by injection, it is not intended that the present invention be limited to this route alone. In general, however, the compositions of the invention are administered by intramuscular or subcutaneous injection. Occasionally, the intravenous or intraperitoneal routes may also be used to administer the compositions of the invention.

In addition to the active ingredient (i.e. the antibody), the compositions of the invention may also comprise a buffering agent, an agent which adjusts the osmolarity thereof, and optionally, one or more further additives, such as carriers, as known in the art.

A preferred buffering agent is phosphate-buffered saline solution (PBS), which solution is also adjusted for osmolarity.

A preferred composition is one lacking a carrier. Such formulations are preferably used for administration by injection, including intramuscular and intravenous injection.

The preparation of pharmaceutical and immunizing compositions is well known in the art and has been described in many articles and textbooks, see e.g., Remington's Pharmaceutical Sciences, Gennaro A. R. ed., Mack Publishing Company, Easton, Pennsylvania, 1990.

It has been shown that the development of autoimmune diabetes in the NOD mouse is marked by the presence of T-cells reactive to the p277 peptide of the HSP 60. It has further been shown that the p277 peptide can be used as a therapeutic vaccine to arrest NOD diabetes [28]. The p277 peptide has been shown to arrest also autoimmune diabetes induced by the Streptozotocin toxin [29]. Likewise, the vaccines according to the invention may also be used to suppress an autoimmune disease.

Furthermore, the vaccines of the invention may also be used to prevent relapses of autoimmune diseases, which characterize many autoimmune diseases. Prevention of a relapse is therefore part of the therapeutic approach to these disorders. The above peptide p277 has been shown to prevent NOD mice diabetes by turning off the anti-p277 immunity early in life. It was later shown to arrest autoimmune process even after it is far advanced [28].

Another possibility is that antibodies against the HSP molecule suppress inflammation by inhibiting the proinflammatory effect of the HSP on the innate immune system. Mycobacterial HSP65 has been shown to induce release of pro-inflammatory cytokines from human monocytic cells [18] and the mammalian HSP60 has been shown to synergize with IFN- γ and to promote pro-inflammatory cytokines like IL-12 and IL-15 [31]. Induction of anti-Mycobacterial / anti-self HSP antibodies may suppress those proinflammatory effects.

Specific immunoglobulins (antibodies) are commonly used for prevention and treatment of infectious diseases (i.e. viral hepatitis). This is termed passive vaccination. Immunoglobulins can also be used to suppress or prevent relapses of autoimmune diseases like ITP (Immune Thrombocytopenic Purpura), Myasthenia Gravis (MG), and other autoimmune diseases [30].

Thus, in yet a further aspect, the invention relates to an antibody directed against at least one peptide according to the invention or functional homologues and derivatives thereof, which can induce the production of said antibody.

The antibodies of the invention may be polyclonal or monoclonal antibodies.

In yet a further aspect, the invention relates to a composition for the passive immunization comprising at least one antibody according to the invention, and may optionally further comprise pharmaceutically acceptable carriers, diluents, additives, excipients and adjuvants. The composition of the present invention is particularly intended for the passive vaccination or immunization against, and treatment of autoimmune or inflammatory disorders, for example, rheumatoid arthritis.

The invention will be described in more detail on basis of the following Examples, which are illustrative only and do not in any way limit the invention. Many modifications and variations of the present invention are possible in light of the present teachings. It is therefore understood, that within the scope of the appended claims, the invention may be practiced otherwise than specifically described.

The following Examples show the anti-MT HSP antibody response of various rats and its correlation with susceptibility to induction of arthritis. Only a limited number of epitopes in the bacterial HSP molecule is recognized by rat antibodies. The repertoire of this antibody differs between resistant and susceptible strains. Resistant strains were found to respond to peptides that are found on the outer surface of the molecule, as well as to the whole molecule. On the other hand, antibodies from naive Lewis rats reacted with a smaller number of peptides, which are less exposed on the

outer surface of the molecule and did not react with the intact HSP. The presence of antibodies against some of the epitopes, as well as the whole MT-HSP, may be associated with resistance to the induction of arthritis and they were therefore named "protective" epitopes.

It has been previously reported that the T cell response to bacterial HSP shows determinant spreading. The present data, given in the following Examples, show that there is a clear B cell determinant spreading as well, and this spreading can occur also spontaneously, namely without intentional vaccination. The B cell epitopes, as will be shown, are different from the T cell epitopes. This observation is of particular significance to the present invention.

Young naive Lewis rats recognized only two bacterial epitopes; peptides 40 and 63. Four months Lewis rats recognized, in addition, peptides 6, 36 and 45 and nine months Lewis rats recognized peptides 7 and 31, in addition to all the other mentioned peptides. Recognition of these peptides is also associated with recognition of the whole bacterial HSP molecule.

The B cell epitope repertoire of the young BN rats is similar to that of the old Lewis rats including only one additional peptide, peptide 59. Lewis rats that were immunized with the CFA responded to all the aforementioned peptides, as well as to two additional peptides, namely 21 and 84.

Although all the anti HSP peptide antibodies found in naive old Lewis rats and in naive young BN rats are referred to as natural antibodies, it is possible that they are elicited as a response to the exposure of these rats to environmental pathogens (as "natural" antibodies may indeed always be) and that the epitope spreading in response to these pathogens occurs in the BN rat more rapidly, earlier and in more strongly than in the Lewis rat. Lewis rats have to be immunized with CFA in order to mimic the natural

response of the BN rats. The similarity of the antibody repertoire of the naive BN rats to that of the immunized Lewis rat supports this possibility.

The nature of the B cell epitopes and the correlation between recognition of certain epitopes and the whole molecule can be better understood from primary and tertiary structure analysis of the molecule, shown hereafter.

To see whether the anti-HSP protective antibodies can be induced by immunization with the "protective" peptides, Lewis rats were immunized with the various peptides, without Freund's adjuvant. Immunization with three peptides, the bacterial peptides 6 and 7, and the mammalian peptide 5, led to production of antibodies against bacterial peptide 6, as well as to an anti-HSP response, showing that antibodies against an "external" peptide will lead to recognition of the whole molecule. Induction of these antibodies also led to disease resistance.

Although the mechanism of disease resistance induced by the natural as well as the induced anti-HSP antibodies has not been yet clarified, it is possible that the antibodies against the MT HSP inhibit the early steps of induction of pathogenic T cells to the peptide by intervening in the antigen processing or the T cell recognition of the pathogenic epitopes. Alternatively they may prevent the effector steps of the pathogenic response by binding to the self HSP-cross reacting target antigen.

The T cell response of AA susceptible Lewis and AA resistant WKA Wistar rats to the bacterial HSP 65kD has been thoroughly studied. It has been shown that in the early post immunization stages the Lewis T cells respond to several determinants found in the N terminal, as well as in the carboxy terminal of the molecule, whereas later a shift to carboxy terminal epitopes has developed. The early T cell response of Wistar rats was similar to that of the late response of the Lewis rats. As the 3D structure of the molecule does

not show the carboxy and the N terminal sites to be in different locations of the molecule, it is not surprising that the B-cell epitopes were found all along the molecule without any selection of either the carboxy or the N terminal of the molecule.

A comparison between the published dominant T cell epitopes and the present B cell epitopes did not reveal common epitopes. To the contrary, the lack of natural antibodies to certain epitopes like 6, 7 or 31 in the naive Lewis rat is associated with an early T cell response to these epitopes, whereas the presence of antibodies to epitopes like 40 and 63 is associated with lack of an early T cell response. Based on these correlations, it may be suggested that the presence of natural antibodies to certain epitopes may actually inhibit T cell response to them, whereas the lack of antibodies enables the T cells to respond to these epitopes. For example, AA susceptible Lewis rats that do not have natural antibodies to the bacterial peptide 31 can develop a T cell response to this peptide, and these pathogenic T cells can induce arthritis.

As previously mentioned, there was a clear correlation between disease resistance and the presence of anti-HSP antibodies. Young naive Lewis rats did not have detectable antibodies against the HSP molecule whereas nine months old Lewis rats developed these antibodies in a significant titer. Parallel to the development of the anti-HSP response, the old rats also became resistant to induction of arthritis. Young Lewis rats acquired both the antibodies and disease resistance after immunization with CFA and the naturally resistant BN rats had anti HSP antibodies spontaneously, without the need for immunization. It is possible therefore that these antibodies bind the bacterial HSP immediately after immunization and prevent it from becoming accessible to the cellular arm of the immune system.

As noted previously, the epitopes "chosen" by the B cells from the bacterial HSP are epitopes that have relatively little homology with the self HSP, most probably as a result of tolerance to self antigens.

Analysis of the anti self (rat) HSP antibody repertoire indeed showed that there is a limited number of epitopes recognized by the rat immunoglobulins in the self HSP molecule. Naive young Lewis rats did not respond to any self peptide neither did they respond to the whole self HSP 60 molecule. BN and post-AA Lewis rats that reacted with 8-10 bacterial HSP epitopes responded to only two epitopes in the self HSP, peptides M5 and M30, as well as to the whole self HSP molecule.

Expression of the mammalian (or self) HSP is upregulated in inflamed synovia of rats with AA [22] and cross-reactive immunorecognition has been found between the Mycobacterial HSP 65kD and endogenous self HSP 60kD at the T-cell level [23-25].

As the anti self antibodies were found only in the resistant rats, it is possible that antibodies that cross react with the self HSP may conceal it from the pathogenic T cells and thus act as protective antibodies.

It is interesting to note that one of the two self protective epitopes is the self peptide 5, which is the homologous rat epitope to the bacterial protective peptide 6. Moreover, immunization with the bacterial peptides 6 and 7 and with the mammalian peptide 5 led to the production of anti bacterial HSP 6 and anti bacterial HSP antibodies, as well as protection against disease induction. Observing the primary structure of these three peptides leads to the conclusion that they express a common motif (V-E--W G-P) which might be the protective motif of these peptides (Figure. 5).

Therefore, the humoral immune response to the bacterial HSP may be aimed at a limited number of potential B-cell epitopes. These epitopes are peptide stretches located between amino acids that serve as bends and spacers, and are found in non-conserved parts of the molecule. Recognition of B-cell epitopes that are exposed on the surface of the molecule leads to binding to the whole molecule and is associated with resistance to induction of arthritis.

This resistance occurs naturally in some strains of rats whereas in others it can be acquired with age or upon immunization with HSP. Immunization with some of the "protecting" epitopes can lead both to disease resistance as well as to the serological profile that is present in the resistant strains.

The present invention can also provide a method for the prediction of susceptibility/predisposition to develop autoimmune arthritis. In the rat system, it has been shown that naive young Lewis rats do not have antibodies against peptide 6 of the HSP, and that they are susceptible to the development of arthritis after exposure to or immunization by HSP. In a similar manner, healthy individuals that lack sub-groups of antibodies against HSP specific peptides may be susceptible to onset of arthritis. The present invention also provides an assay for the assessment and determination of susceptibility/predisposition to arthritis. The assay can be performed by ELISA, in which the peptides will be bound to the solid phase and serum samples added, followed by adding anti human Igs. Other known immunological analysis techniques can also be used.

The invention will be described in more detail on hand of the following examples, which are illustrative only and do not limit the invention thereto.

Examples

Materials

Animals: Female inbred Lewis rats, 6 weeks or 9 months old, were obtained from Harlan Lab. Israel. Female Brown-Norway (BN) rats, 6 weeks old, were obtained from Harlan Sprague-Dawley, USA.

Antigens and antibodies: Recombinant HS P65 of Mycobacterium Tuberculosis was a gift from Dr. M. Singh (The WHO Recombinant Protein Bank, Germany). Recombinant mammalian HSP 60 was purchased from StressGen Biothec. Corp. (Victoria, BC, Canada). Synthetic peptides of MT HSP 65 were a gift from Dr. L. Adorini (The Roche Milano Ricerche, Milano, Italy). Synthetic peptides of the mammalian HSP 60 were a gift from Dr. I. Cohen (The Weizmann Institute, Rehovot, Israel). Goat anti Rat IgG conjugated to alkaline-phosphatase was purchased from Jackson ImmunoResearch Lab. Inc. (Avonsdale, PA).

Methods

Induction and Clinical Assessment of Adjuvant Arthritis: Lewis rats were injected with 1 mg of Mycobacterium Tuberculosis H37Ra (Difco, Detroit, MI) in Complete Freund's Adjuvant (Difco) subcutaneously at the base of the tail. Severity of Arthritis (arthritis index) was assessed blindly as follows: 0 - no arthritis; 1 - redness of the joint; 2 - redness and swelling of the joint. The ankle and tarsal-metatarsal joints of each paw were scored. A maximum score of 16 can be obtained, but a score above 8 indicates a severe disease.

Dot Blots assay: Antigens were dissolved in PBS and samples of 1 µg were adsorbed on Nitrocellulose paper. The paper was air-dried and incubated with BSA 1% in PBS for 20 min. to block non-specific binding. The samples were then washed in PBS-Tween 0.05% and incubated with rat sera diluted 1:100 in BSA-PBS, for 90 min. at room temp. Samples were washed and incubated with goat anti rat antibody conjugated to alkaline phosphatase diluted 1:1000 in BSA-PBS for 90 min. at RT. After re-washing the color

reaction was developed by adding a mixture of BCIP-NBT (Sigma-Fast, Sigma) to the cells for 15 min. The reaction was stopped by the addition of tap water.

ELISA: Flat-bottomed 96 well plates (Corning) were coated with mammalian HSP 60, or Mycobacterial HSP 65 (10 µg/ml) in carbonate buffer pH 9.6 overnight at 4°C.

After extensive washing with PBS-Tween 0.05% plates were incubated with blocking buffer containing 1% BSA (Sigma) for 60 min. at RT.

HSP peptides were attached to plates pre-treated with glutaraldehyde according to Kasprzyk *et al.* [26]. Shortly, plates were coated with 100µl/well of 5% w/v of glutaraldehyde in PBS for 1 hour at room temp. Plates were washed thoroughly with PBS and peptides (1 µg/100µl) were added to each well, incubated overnight at 4°C. Plates were shaken dry and blocked with BSA 1% in PBS.

Plates coated with either HSP or peptides were washed again and incubated with rat sera diluted 1:100 with PBS-Tween 0.01% for 90 min. at room temp. After re-washing the plates were incubated with Goat anti rat IgG or IgM conjugated to alkaline-phosphatase for 60 min. at room temp. The presence of antibodies was revealed by addition of the substrate PNP (NP 100, Chemicon, Temecula, CA) to the plates. Optical density was measured photometrically at 405 nm.

Amino Acid Comparison: "Pileup" and "pretty" programs (GCG – Wisconsin package, v.9.0) were used to compare amino acid sequences of three HSP 60 (Mycobacterium Tuberculosis, rat and human).

Structure Analysis: RasMol v. 2.6 program and the 3D structure of the *E.coli* complex GroEL-GroES (pdb ID: 1AON reference) were used to analyze the position of epitopes.

Since the crystal structure of MT HSP 65kD is not yet completely known, a three-dimensional model for the tertiary structure of MT HSP 65kD based on the solved crystal structure of GroEL from *E. coli* (pdb ID: 1GRL) was used as template. This model was built by programs for comparative protein modeling.

Modulation of AA by mycobacterial and mammalian HSP peptides: HSP 65 derived peptides were tested for their ability to modulate the appearance or severity of AA in Lewis rats. Rats were immunized with 100 µg of each peptide in PBS, three weeks (3W), 2W and 1W before induction of AA by MT. Control rats received PBS. Rats were bled for testing antibody presence before injection of MT and 30 days post MT injection.

DNA Vaccine preparation: A synthetic oligoDNA, having the SEQ ID No. 5, encoding the oligopeptide Mycobacterium Tuberculosis HSP 65kD No. 6, presented in Table 1, was cloned into the commercially available mammalian expression vector, pTARGET (Programa, Madison, WI, USA), having the restriction map depicted in Fig. 6. The cloning was carried out according to the manufacturer's instructions.

The plasmid construct was then transferred into *E. coli* JM109 strain and expanded to large scale for further plasmid purification, using the DNA purification system Wizard Plus Maxipreps kit (Programa, Madison, WI, USA).

Animal vaccination: Lewis rats were pre-treated with Bupivaccine (Astra) two days prior to vaccination and later disease induction. The rats were

then twice injected with 100 µg of the DNA construct, into the tibialis anterior muscle, with a week interval between the injections.

RESULTS

The interaction of rat Ig with whole Mycobacterial HSP 65 and its peptides

Previous experiments conducted by the inventors showed that Ig's from AA resistant naive rats (i.e. BN or Fisher) as well as Lewis rats that recovered from AA (post AA Lewis rats), were able to suppress the induction of AA in naive Lewis rats and bound to the bacterial HSP 65 in a dot blot assay. To obtain a more quantitative evaluation of this binding, the interaction of Ig's from these rats with the whole molecule of the Mycobacterial HSP 65, known to be associated with AA in Lewis rats, was tested by Dot-Blot and ELISA.

It was found that Ig's from 6-8 week old BN rats, and post AA Lewis rats, reacted strongly with the HSP while no reaction was found when Ig's from naive Lewis rats were tested. Interestingly, it was found that Ig's from nine months old naive Lewis rat also reacted with the HSP.

To define the epitopes recognized by the anti bacterial HSP antibodies, the inventors tested by Dot-Blot the interaction of Ig's from naive young BN rats and post AA Lewis rats with 90 16-mer synthetic peptides of the Mycobacterial 65 kD HSP. Ig's from naive young Lewis rats served as control.

Only 10 peptides out of the 90 peptides tested (Table 2) reacted with the immunoglobulins tested. All of the rats immunoglobulins reacted with two peptides: 40 (residues 235-250) and 63 (residues 373-388). When these rats age, they acquire antibodies against additional peptides, and a similar profile to that of old Lewis rats is found in young naive BN rats, and Lewis

rats that were immunized with CFA reacted also with peptides 21 (residues 121-136) and 84 (residues 499-514). It is noted that although naive Lewis rats do not recognize the whole molecule of HSP 65kD, its Ig's can interact with certain peptides of this molecule, without any effect on susceptibility to AA.

Table 2

Antibodies to Mycobacterial HSP 65 Peptides

Peptide Sequence	21-136	84-499	514-364	37-52	7-181	31-196	6-314	36-211	45-265	40-280	63-236	251-388	HSP-65 Susceptibility	Disease
Strain														
Lew-6w	-	-	-	-	-	-	-	-	-	+	+	+	-	8/10
Lew-4m	-	-	-	-	-	-	+	+	+	+	+	+	-	3/5
Lew-9m	-	-	-	+	+	+	+	+	+	+	+	+	+	0/7
BN-6w	-	-	+	+	+	+	+	+	+	+	+	+	++	0/10
Lew-Post AA	+	+	+++	+	+	+	+++	+++	++	++	++	++	++	0/10

O.D. <0.15 = -; 0.16 - 0.45 = +; 0.46 - 0.75 = ++; >0.75 = +++

Binding of rat Ig's with the mammalian HSP 60 and its peptides

Previous studies have shown that certain bacterial HSP peptides may trigger self HSP reactive T-cells with disease suppressive regulatory potential. To analyze the anti self-HSP antibody repertoire of these rats, the reactivity of Ig's from naive and post AA Lewis rats as well as from naive BN rats to whole mammalian HSP 60 was tested by ELISA.

The results presented in Table 3 indicate that that naive and four months old Lewis rats do not possess anti self-HSP 60 antibodies, whereas nine months old Lewis rats, young BN rats and post-AA Lewis rats had significant binding to the self-HSP (Table 3). Some naive Lewis rats had very low concentrations of the antibodies.

Table 3

Antibodies to Mammalian HSP 60 Peptides

Peptide Sequence	M 5 61-80	M 30 436-455	M-HSP 60	Disease Susceptibility
---------------------	-----------	--------------	----------	---------------------------

Strain

Lew-6w	-	-	-	8/10
Lew-4m	-	-	-	3/3
Lew-9m	++	++	+	0/7
BN-6w	+	+	+	0/10
Lew-Post AA	+++	++	+	0/10

O.D.: <0.15 = -; 0.16 - 0.45 = +; 0.46 - 0.75 = ++; >0.75 = +++

Immunoglobulins from naive Lewis and BN rats and post-AA Lewis rats were tested for binding to 38 synthetic 20-mer peptides of the mammalian HSP 60 by Dot-Blot. It was found that Ig's derived from BN and post-AA Lewis rats, but not from naive Lewis rats, reacted with 2 peptides only: peptide 5 (residues 61-80) and peptide 30 (residues 436-455). Quantitative

analysis of this binding as well as the binding of immunoglobulins from four and nine months old Lewis rats confirmed the dot blot findings (Table 3).

Amino acid comparison

The HSP 60 family is highly conserved: MT-HSP 65 and its mammalian homologues (rat or human) show 48% identity. In Fig. 1, the three amino acid sequences of the MT-HSP 65, HSP 60 from rat and human are compared. The consensus sequence of these three proteins is shown too. The epitopes that were found to be relevant in this study are shown in **Bold** and Underlined.

3D structure analysis

Tertiary structure plays an important role for B-cell epitope recognition. In a first approach, a simple computer program was provided, that could predict where to find potential B-cell epitopes by screening the primary structure of the peptide. The algorithm is based on a previous analysis by Warren *et al.* [27] of the Myelin Basic Protein to locate potential epitopes for B-cell. According to their analysis, two sorts of amino acids can be defined:

- "Molecular spacers": These are short-chain residues (side chains of one carbon or less) that could provide a molecular gap for adjacent long-chain amino acids. Three amino acids that fit this definition are: Glycine (G), Alanine (A) and Serine (S).
- "Molecular bends": Proline (P) residues that can cause disruptions in secondary structure.

A minimal length of 9 residues for these potential epitopes was set. Following these rules, six series of consecutive long-chain residues (side chains of two carbons or more) located between molecular spacers and/or molecular bends were found (Table 4).

Table 4
Potential epitopes of MT HSP 65kD

Location of the peptide (aa residues)	Sequence of the peptide	Length	Experimental peptide matching
35-43	<u>G-RNVVLEKKW-G</u>	9	6,7
123-132	<u>A-VEKVTETLLK-G</u>	10	21
135-143	<u>A-KEVETKEQI-A</u>	9	21
319-332	RKVVVTKDAETTIVE	14	none
357-367	<u>S-DYDREKLQERL-A</u>	11	59
383-396	<u>A-TEVELKERKHRIED-A</u>	14	63
183-195	<u>G-IQLELTEGMRFDK-G</u>	13	31
259-270	<u>S-TLVVNKIRGTFK-S</u>	12	45

The peptide was screened by a computer program and consecutive long-chain residues (side chains of two carbons or more) located between molecular spacers and/or molecular bends are shown (the 6 first peptides). The two peptides below them are the consecutive chain that contain at most one molecular spacer (glycine).

Five of six series that were identified by these rules fit amino acid sequences that were found to be experimentally recognized by B-cell antibodies (Table 1). Consequently, in order to find more epitopes, the program was run with a slight change, namely search of epitopes that contain at most one molecular spacer (G, S or A). The minimal length was set at 12 residues (instead of 9 previously) in order to lower the background (i.e., a penalty of three residues was set to compensate the gap). Two new sequences were identified, that were also found to be experimentally recognized by B-cell antibodies (31, 45; see Table 1). The molecular spacer was glycine in these two cases.

In order to better understand the implications of the tertiary structure of MT HSP 65kD and to locate these different amino acid sequences on the whole molecule, a model for the tertiary structure of MT HSP 65kD based on the crystal structure of *E. coli* GroEL (Fig. 3) was used.

Structure analysis confirmed that the experimentally recognized epitopes located on the surface of the protein can provide a potential site to antibodies binding. Peptides 6, 7, 21, 31, 59 were those that were found to be the most exposed whereas peptides 36, 40, 45, 63 and 84 are partially exposed.

The single potential epitope that was not recognized experimentally (residues 318-331) seems to be "buried" in the molecule.

Although there is a marked homology between MT HSP 65kD and mammalian HSP 60kD, most of the peptides that were found to be recognized by the anti-MT HSP 65 antibodies did not show high residues homology with the mammalian HSP. This may be due to the tolerance to self, that protects the rats from developing an autoimmune autoantibody response to their own HSP 60. Two peptides, 6 and 45, did not seem to conform to this rule as they had sites showing high homology to the self HSP.

These findings may be explained for both peptides as follows:

As to peptide 6 (residues 31-46): antibodies were found to bind peptide 7 (residues 37-52) which overlap the polymorphic part of this peptide, but not peptide 5 (residues 25-40) representing the region homologous with the mammalian HSP. It seems therefore, that these antibodies are directed against the polymorphic (non-self) region of peptide 6 (residues 40-46). It can also provide a hypothesis concerning the "protective" ability of this

peptide, partial homology to the mammalian HSP 60 sequence may be responsible for this protective effect.

As to peptide 45 (residues 265-280): This peptide can be divided into two consecutive regions: one polymorphic (residues 265-271) and the second highly conserved (residues 271-280). Analysis of the three-dimensional structure shows that the polymorphic region is the exposed region, whereas the conserved region seems to be "buried" in the whole molecule (not shown). Therefore, it is possible that the antibodies that bind peptide 45 are mainly directed against the exposed polymorphic region.

No particularity concerning the secondary structure and the repartition of hydrophobic/polar residues in these epitopes was noticed (both experimentally and computer recognized). Generally, the experimentally recognized epitopes tend to be hydrophobic (9-12 hydrophobic residues out of 16), but for peptide 59 that is highly polar (13 residues out of 16).

With reference to the Figures, Fig. 2 shows the location of bacterial peptides 6, 7 and 31 on the three dimensional structure of the *E. Coli* GroEL-GroES complex and Fig. 3, as stated, shows the same peptides on a model of the MT HSP 65 based on the structure of GroEL *E. Coli* with a space-filling and secondary structure representations.

Analysis of the ability of peptides to immunize against AA

To test whether active immunization with bacterial or mammalian HSP peptides that are recognized by protective immunoglobulins can induce protection against AA, Lewis rats were immunized with the mycobacterial peptides 6, 7, 21, 31, 36, 45, 84, that bound antibodies from resistant Lewis rats ("protective" peptides), with some non-reactive mycobacterial HSP 65 peptides: peptide 26 (residues 151-166), 28 (residues 163-178) or peptide 70 (residues 415-430), and with the mammalian peptide 5.

Rats were injected 3 times intraperitoneally (IP), with one week intervals between injections before induction of AA with MT.

Fig. 4 shows that only pre-immunization of rats with the bacterial peptides 6 and 7 and the mammalian peptide 5 resulted in a significant suppression of disease severity.

Immunization with these "protective" peptides also resulted in the production of antibodies against peptide 6 as well as against the whole MT HSP 65 (Table 5).

Table 5
Anti HSP Antibodies in Immunized Lewis Rats

Antigen Immunizing Peptide	6	7	M5	MT-HSP 65
PBS	-	-	-	-
6	++	-	-	++
7	+	-	-	+
M5	+	-	-	+

O.D.:

<0.15 = -; 0.16 - 0.45 = +; 0.46 - 0.75 = ++; >0.75 = +++

References:

1. Pearson, C.M., *Proc. Soc. Exp. Biol. Med.* 91:95-101 (1956)
2. Pearson, C.M. & Wood, F.D., *Arthritis Rheum.* 2:440 (1959)
3. Waxman, B.H. and Wemersten, C., *Int. Arch. Allergy* 23:129 (1963)
4. Ulmanský, R., *et al.*, *Eur. J. Immunol.* 25:952-957 (1995).
5. Hogervorst, E.J.M., *et al.* *Eur. J. Immunol.* 21:1289-1296 (1991)
6. Griffiths, M.M., *et al.*, *Arthritis Rheum.* 36:254 (1993)
7. Van Eden, W., *et al.*, *Nature (Lond.)* 331:171-173 (1988)
8. Holoshitz, J., *et al.*, *Science (Wash. DC)* 219:56-58 (1983)
9. Holoshitz, J., *et al.*, *Lancet* 2:305-309 (1986)
10. Res, P.C.M., *et al.*, *Lancet* 2:478-480 (1988)
11. Gaston, J.S.H., *et al.*, *J. Immunol.* 143:2494-2500 (1984)
12. Gaston, J.S.H., *et al.*, *J. Exp. Med.* 171:831-841 (1990)
13. Quayle, A.J., *et al.*, *Eur. J. Immunol.* 22:1315-1322 (1992)
14. Henwood, J., *et al.*, *Eur. J. Immunol.* 23:1256-1265 (1992)
15. Billingham, M.E.J., *et al.*, *J. Exp. Med.* 171:339-344 (1990)
16. Hogervorst, E.J.M., *et al.*, *Int. Immunol.* 4:719 (1992)
17. Young, X.D., *et al.*, *Clin. Exp. Immunol.* 81:189-194 (1990)
18. Friedland, J.S., *et al.*, *Clin. Exp. Immunol.* 91: 58-62 (1993)
19. Anderston, S.M., *et al.*, *J. Immunol.* 152:3656-3664 (1994)
20. Moudgil, K.D., *et al.*, *J. Exp. Med.* 185:1307-1316 (1997)
21. Jindal, S., *et al.*, *Mol. Cell. Biol.* 9:2279-2283 (1989).
22. Kleinau, S.K., *et al.*, *Scand. J. Immunol.* 33:195-202 (1991)
23. Munk, M.E., *et al.*, *J. Immunol.* 143:2844 (1989)
24. Anderston, S.M., *et al.*, *Eur. J. Immunol.* 23:33 (1993)
25. Shinnik, T., *et al.*, *Eur. J. Immunol.* 22:1315-1322 (1992)
26. Kasprzyk, P.G., *et al.*, *Anal. Biochem.* 174:224 (1988)
27. Warren, K.G., *et al.*, *Proc. Natl. Acad. Sci. USA* 92:11061 (1995)
28. Elias, D., *et al.*, *Lancet* 343:704-706 (1994)
29. Elias, D., *et al.*, *Diabetes* 45:1168-1172 (1996)

30. Jordan, S.C. and Toyoda, M., Clin. Exp. Immunol. 97:31-38 (1994)
31. Chen, W., *et al.*, J. Immunol 162:3212-3219 (1999)
32. Barker *et al.*, Autoimmunity 14:73-77, (1992)

Claims:

1. A peptide comprising the amino acid sequence substantially as denoted by SED ID No. 1 and biologically functional homologues and derivatives thereof.
2. A peptide as claimed in claim 1 having the amino acid sequence substantially as denoted by SED ID No. 2 and biologically functional homologues and derivatives thereof.
3. A peptide as claimed in claim 1 having the amino acid sequence substantially as denoted by SED ID No. 3 and biologically functional homologues and derivatives thereof.
4. A peptide comprising the amino acid sequence substantially as denoted by SED ID No. 4 and biologically functional homologues and derivatives thereof.
5. A peptide as claimed in any one of claims 1 to 4, being a synthetic peptide.
6. A chemically modified peptide according to claim 5.
7. A peptide as claimed in any one of claims 1 to 6 capable of conferring immunity against autoimmune and/or inflammatory disorders.
8. A nucleic acid sequence encoding a peptide as claimed in any one of claims 1 to 4.
9. A DNA sequence as claimed in to claim 8.
10. A DNA sequence as claimed in claim 9 comprising the nucleic acid sequence substantially as denoted by SQE ID No. 5 and biologically functional homologues and derivatives thereof.
11. A DNA construct comprising a nucleic acid sequence as claimed in claim 8.
12. A DNA construct comprising the DNA sequence as claimed in claim 9 or 10 or biologically functional homologues and/or derivatives thereof.
13. A vaccine comprising as active ingredient an effective vaccinating amount of at least one peptide as claimed in any one of claims 1 to 7,

optionally further comprising pharmaceutically acceptable carrier, diluent, additive or adjuvant.

14. A vaccine comprising as active ingredient a DNA sequence as claimed in any one of claims 1 to 8, optionally further comprising pharmaceutically acceptable carrier, diluent, additive or adjuvant.
15. A vaccine as claimed in claim 13 or claim 14, for conferring immunity against autoimmune or inflammatory disorders.
16. The vaccine as claimed claim 15 for conferring immunity against arthritis.
17. An antibody directed against a peptide comprising the amino acid sequence substantially as denoted by SED ID No. 1 or against biologically functional homologues and derivatives thereof.
18. An antibody as claimed in claim 17, directed against a peptide having the amino acid sequence denoted by SED ID No. 1.
19. An antibody directed against a peptide having the amino acid sequence substantially as denoted by SED ID No. 2 or against biologically functional homologues and derivatives thereof.
20. An antibody as claimed in claim 19, directed against a peptide having the amino acid sequence denoted by SED ID No. 2.
21. An antibody directed against a peptide having the amino acid sequence substantially as denoted by SED ID No. 3 or against biologically functional homologues and derivatives thereof.
22. An antibody directed against a peptide comprising the amino acid sequence substantially as denoted by SED ID No. 4 or against biologically functional homologues and derivatives thereof.
23. An antibody as claimed in claim 22, directed against a peptide having the amino acid sequence denoted by SED ID No. 4.
24. A composition for the passive immunization against an autoimmune or inflammatory disorder comprising a pharmaceutically effective amount of an antibody as claimed in any one of claims 17 to 23.

25. A composition as claimed in claim 24, for the prevention or treatment of autoimmune or inflammatory disorder.
26. A method for predicting the susceptibility/predisposition of an individual to arthritis by testing a sample of serum from said individual for the presence of antibodies directed against a peptide as claimed in any one of claims 1 to 5, by suitable immunoassay techniques.

1/7

			1	6	25
HSP 65 - <u>M.T.</u>	-----	-----	-----	MAKTI	AYDEEARRGL ERGLNALADA
HSP 60 - <u>RAT</u>	MLRLPTVLRQ	MRPVSRLALP	HLTRAYAKDV	KFGADARALM	LQGVDLLADA
HSP 60 - <u>HUMAN</u>	MLRLPTVFRQ	MRPVSRLVLP	HLTRAYAKDV	KFGADARALM	LQGVDLLADA

Consensus -----AK-- --AR-- --G---LADA

		26		75
HSP 65 - <u>M.T.</u>	VKVTLGPKGR	NVLEKKWGA	PTITNDGVSI	AKEIELEDPY EKIGAEVLVKE
HSP 60 - <u>RAT</u>	VAVTMGPKGR	TVLIEQSWG	PKVTKDGVTV	AKSIDLKDKY KNIGAKLVQD
HSP 60 - <u>HUMAN</u>	VAVTMGPKGR	TVLIEQSWG	PKVTKDGVTV	AKSIDLKDKY KNIGAKLVQD

Consensus V-VT-GPKGR -V--E--WG- P--T-DGV-- AK-I-L-D-Y --IGA-LV--

6-7(31-52 AA)

		76		125
HSP 65 - <u>M.T.</u>	VAKKTDDVAG	DGTTTATVLA	QALVREGLRN	VAAGANFLGL KRGISKAVKE
HSP 60 - <u>RAT</u>	VAANTNEEAG	DGTTTATVLA	RSIAKEGFEX	ISKGANPVEI RRGVMLAVDA
HSP 60 - <u>HUMAN</u>	VAANTNEEAG	DGTTTATVLA	RSIAKEGFEX	ISKGANPVEI RRGVMLAVDA

Consensus VA--T---AG DGTTTATVLA ----EG--- ---GANP--- -RG---AV--

21 (121-136 AA)

		126		174
HSP 65 - <u>M.T.</u>	VTETLLKGAK	EVETKEQIAA	TAAISA.GDQ	SIGDLIAEAM DKVGNQGVIT
HSP 60 - <u>RAT</u>	VLAELKKQSK	FVTTPEEIAQ	VATISANGDK	DIGNIISDAM KKVGRKGVIT
HSP 60 - <u>HUMAN</u>	VLAELKKQSK	FVTTPEEIAQ	VATISANGDK	EIGNIISDAM KKVGRKGVIT

Consensus V---L-K-K -V-T-E-IA- -A-ISA-GD- -IG--I--AM -KVG--GVIT

		175		224
HSP 65 - <u>M.T.</u>	VEESNTFGLQ	LELTGMRFD	RGVVISGYFVT	DPERQPAVLE DPYILLVSSK
HSP 60 - <u>RAT</u>	VKGKTLNDE	LELTGMRFD	RGVVISPYFIN	TSKGQKCEFO DAYVLLSEKK
HSP 60 - <u>HUMAN</u>	VKGKTLNDE	LELTGMRFD	RGVVISPYFIN	TSKGQKCEFO DAYVLLSEKK

Consensus V---T--- LE--EGM-FD -GYIS-YF-- ----Q---- D-Y-LL---K

31 (181-196 AA)

36 (211-226 AA)

		225		274
HSP 65 - <u>M.T.</u>	VSTVKDLLPL	LEKVIGAGKP	LLITIAEDVEG	EALSTLVVNK IRTGFFKSVAV
HSP 60 - <u>RAT</u>	ISSVQSIVPA	LEIANARPK	LVITIAEDVDG	EALSTLVNLR LEVGLQVVAV
HSP 60 - <u>HUMAN</u>	ISSIQSIVPA	LEIANARPK	LVITIAEDVDG	EALSTLVNLR LEVGLQVVAV

Consensus -S-----P- LE-----KP L-IIAEDV-G EALSTLV-N- -----VAV

40 (236-251 AA)

45 (265-280 AA)

Fig. 1

217

	275		323
HSP 65 - <u>M.T.</u>	<u>KAPGFGDRRK</u> AMLQDMAILT GGQVISEE.V GLTLENADLS LLGKARKVVV		
HSP 60 - <u>RAT</u>	<u>KAPGFGDNRK</u> NQLKDMAIAT GGAVFGEEGL NLNLEDVQAH DLGKVGEEVIV		
HSP 60 - <u>HUMAN</u>	<u>KAPGFGDNRK</u> NQLKDMAIAT GGAVFGEEGL TLNLEDVQPH DLGKVGEEVIV		
Consensus	<u>KAPGFGD</u> -RK --L-DMAI-T GG-V--EE-- -L-LE----- -LGK---V-V		
	324		373
HSP 65 - <u>M.T.</u>	TKDETTIVEG AGDTDAIAGR VAQIRQEIEN SDSDYDREKL QERLAKLAGG		
HSP 60 - <u>RAT</u>	TKDDAMLLKG KGDKAHIEKR IQEITEQLDI TTSEYEKKL NERLAKLSDG		
HSP 60 - <u>HUMAN</u>	TKDDAMLLKG KGDKAQIEKR IQEILEQLDV TTSEYEKKL NERLAKLSDG		
Consensus	TKD-----G -GD---I--R ---I----- -S-Y--EKL -ERLAKL--G		
		59 (349-364 AA)	
	374		423
HSP 65 - <u>M.T.</u>	<u>VAVIKAGAAT</u> EVELKERKHR IEDAVRNAKA AVEEGIVAGG GVTLTQAAPT		
HSP 60 - <u>RAT</u>	<u>VAVLKVGGTS</u> DVEVNEKKDR VTDALNATRA AVEEGIVLGG GCALLRCIPA		
HSP 60 - <u>HUMAN</u>	<u>VAVLKVGGTS</u> DVEVNEKKDR VTDALNATRA AVEEGIVLGG GCALLRCIPA		
Consensus	VAV-K-G--- -VE--E-K-R --DA-----A AVEEGIV-GG G--LL---P-		
		63 (373-388 AA)	
	424		472
HSP 65 - <u>M.T.</u>	LDELK.LEGD EATGANIVKV ALEAPLKQIA FNSGLEPGVV AEKVRNLPAG		
HSP 60 - <u>RAT</u>	LDSLKPANED QKIGIEIIR ALKIPAMTIA KNAGVEGSLI VEKILQSSSE		
HSP 60 - <u>HUMAN</u>	LDSLTPANED QKIGIEIIR TLKIPAMTIA KNAGVEGSLI VEKIMQSSSE		
Consensus	LD-L-----D ---G--I-K- -L--P---IA -N-G-E---- -EK-----		
	473		522
HSP 65 - <u>M.T.</u>	HGLNAQTGVY EDLLAAGVAD PVKVTRSALQ NAASTAGLFL TTEAVVADKP		
HSP 60 - <u>RAT</u>	VGVDAMLGDF VNMVEKGIIID PTKVVRTALL DAAGVAPLLT TAEAVVTEIP		
HSP 60 - <u>HUMAN</u>	VGVDAMAGDF VNMVEKGIIID PTKVVRTALL DAAGVASLLT TAEVVVTEIP		
Consensus	-G--A--G-- -----G--D P-KV-R-AL- -AA--A-L-- T-E-VV---P		
		84 (499-514 AA)	
	523	540	
HSP 65 - <u>M.T.</u>	EKEKASVPGG GDMGGMDF-- -----		
HSP 60 - <u>RAT</u>	KEEKD..PGM GAMGGMGGGM GGGMF		
HSP 60 - <u>HUMAN</u>	KEEKD..PGM GAMGGMGGGM GGGMF		
Consensus	--EK---PG- G-MGGM-----		

Fig. 1(continued)

3/7




Fig. 2

4/7




Fig. 3A




Fig. 3B

5/7




Fig. 4

6/7

The "Protective" Motif

MT	HSP Peptide 6- (31-46)	G P K G R N <u>V</u> V L <u>E</u> K K <u>W</u> <u>G</u> A <u>P</u>
MT	HSP Peptide 7- (37-52)	<u>V</u> V L <u>E</u> K K <u>W</u> <u>G</u> A <u>P</u> T I T N D G
Rat	HSP Peptide 5- (36-55)	T <u>V</u> I I <u>E</u> Q S <u>W</u> <u>G</u> S <u>P</u> K V T K D D G V T V
Common Motif		V = = E - - W G - P

Fig. 5

<110> Hadasit Medical Research Services & Development Ltd

<120> Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof

<130> 6433/WO/99

<140>

<141>

<150> 60/107,213

<151> 1998-11-05

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 22

<212> PRT

<213> Mycobacterium tuberculosis

<400> 1

Gly	Pro	Lys	Gly	Arg	Asn	Val	Val	Leu	Glu	Lys	Lys	Trp	Gly	Ala	Pro
1				5				10					15		

Thr	Ile	Thr	Asn	Asp	Gly
					20

<210> 2

<211> 16

<212> PRT

<213> Mycobacterium tuberculosis

<400> 2

Gly	Pro	Lys	Gly	Arg	Asn	Val	Val	Leu	Glu	Lys	Lys	Trp	Gly	Ala	Pro
1				5				10					15		

<210> 3

<211> 16

<212> PRT

<213> Mycobacterium tuberculosis

<400> 3

Val Val Leu Glu Lys Lys Trp Gly Ala Pro Thr Ile Thr Asn Asp Gly
 1 5 10 15

<210> 4

<211> 20

<212> PRT

<213> Human

<400> 4

Thr Val Ile Ile Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp
 1 5 10 15

Gly Val Thr Val
 20

<210> 5

<211> 67

<212> DNA

<213> Human

<400> 5

gccgccatgg gaccaaaggg acgcaacgtg gtactagaga agaaatgggg cgcgcgctag 60
 ctcgaga 67

<210> 6

<211> 540

<212> PRT

<213> Mycobacterium tuberculosis

<400> 6

Met Ala Lys Thr Ile Ala Tyr Asp Glu Glu Ala Arg Arg Gly Leu Glu
 1 5 10 15

Arg Gly Leu Asn Ala Leu Ala Asp Ala Val Lys Val Thr Leu Gly Pro
 20 25 30

Lys Gly Arg Asn Val Val Leu Glu Lys Lys Trp Gly Ala Pro Thr Ile
 35 40 45

Thr Asn Asp Gly Val Ser Ile Ala Lys Glu Ile Glu Leu Glu Asp Pro
 50 55 60

Tyr Glu Lys Ile Gly Ala Glu Leu Val Lys Glu Val Ala Lys Lys Thr
 65 70 75 80

Asp Asp Val Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala Gln
 85 90 95

Ala Leu Val Arg Glu Gly Leu Arg Asn Val Ala Ala Gly Ala Asn Pro
 100 105 110

Leu Gly Leu Lys Arg Gly Ile Glu Lys Ala Val Glu Lys Val Thr Glu
 115 120 125

Thr Leu Leu Lys Gly Ala Lys Glu Val Glu Thr Lys Glu Gln Ile Ala
 130 135 140

Ala Thr Ala Ala Ile Ser Ala Gly Asp Gln Ser Ile Gly Asp Leu Ile
 145 150 155 160

Ala Glu Ala Met Asp Lys Val Gly Asn Glu Gly Val Ile Thr Val Glu
 165 170 175

Glu Ser Asn Thr Phe Gly Leu Gln Leu Glu Leu Thr Glu Gly Met Arg
 180 185 190

Phe Asp Lys Gly Tyr Ile Ser Gly Tyr Phe Val Thr Asp Pro Glu Arg
 195 200 205

Gln Glu Ala Val Leu Glu Asp Pro Tyr Ile Leu Leu Val Ser Ser Lys
 210 215 220

Val Ser Thr Val Lys Asp Leu Leu Pro Leu Leu Glu Lys Val Ile Gly
 225 230 235 240

Ala Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Val Glu Gly Glu Ala
 245 250 255

Leu Ser Thr Leu Val Val Asn Lys Ile Arg Gly Thr Phe Lys Ser Val
 260 265 270

Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Ala Met Leu Gln
 275 280 285

Asp Met Ala Ile Leu Thr Gly Gly Gln Val Ile Ser Glu Glu Val Gly
 290 295 300

Leu Thr Leu Glu Asn Ala Asp Leu Ser Leu Leu Gly Lys Ala Arg Lys
 305 310 315 320

Val Val Val Thr Lys Asp Glu Thr Thr Ile Val Glu Gly Ala Gly Asp
 325 330 335

Thr Asp Ala Ile Ala Gly Arg Val Ala Gln Ile Arg Gln Glu Ile Glu
 340 345 350
 Asn Ser Asp Ser Asp Tyr Asp Arg Glu Lys Leu Gln Glu Arg Leu Ala
 355 360 365
 Lys Leu Ala Gly Gly Val Ala Val Ile Lys Ala Gly Ala Ala Thr Glu
 370 375 380
 Val Glu Leu Lys Glu Arg Lys His Arg Ile Glu Asp Ala Val Arg Asn
 385 390 395 400
 Ala Lys Ala Ala Val Glu Glu Gly Ile Val Ala Gly Gly Gly Val Thr
 405 410 415
 Leu Leu Gln Ala Ala Pro Thr Leu Asp Glu Leu Lys Leu Glu Gly Asp
 420 425 430
 Glu Ala Thr Gly Ala Asn Ile Val Lys Val Ala Leu Glu Ala Pro Leu
 435 440 445
 Lys Gln Ile Ala Phe Asn Ser Gly Leu Glu Pro Gly Val Val Ala Glu
 450 455 460
 Lys Val Arg Asn Leu Pro Ala Gly His Gly Leu Asn Ala Gln Thr Gly
 465 470 475 480
 Val Tyr Glu Asp Leu Leu Ala Ala Gly Val Ala Asp Pro Val Lys Val
 485 490 495
 Thr Arg Ser Ala Leu Gln Asn Ala Ala Ser Ile Ala Gly Leu Phe Leu
 500 505 510
 Thr Thr Glu Ala Val Val Ala Asp Lys Pro Glu Lys Glu Lys Ala Ser
 515 520 525
 Val Pro Gly Gly Gly Asp Met Gly Gly Met Asp Phe
 530 535 540

<210> 7
 <211> 573
 <212> PRT
 <213> Rat

<400> 7
 Met Leu Arg Leu Pro Thr Val Leu Arg Gln Met Arg Pro Val Ser Arg
 1 5 10 15

Ala Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
 20 25 30

Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
 35 40 45

Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
 50 55 60

Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
 65 70 75 80

Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
 85 90 95

Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
 100 105 110

Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
 115 120 125

Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
 130 135 140

Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
 145 150 155 160

Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
 165 170 175

Asn Gly Asp Lys Asp Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
 180 185 190

Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
 195 200 205

Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
 210 215 220

Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
 225 230 235 240

Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Val Gln Ser
 245 250 255

Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
 260 265 270

Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu
 275 280 285

Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
 290 295 300

Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
 305 310 315 320

Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Asn Leu Asn Leu Glu Asp
 325 330 335

Val Gln Ala His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
 340 345 350

Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala His Ile Glu
 355 360 365

Lys Arg Ile Gln Glu Ile Thr Glu Gln Leu Asp Ile Thr Thr Ser Glu
 370 375 380

Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly
 385 390 395 400

Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu
 405 410 415

Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val
 420 425 430

Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile
 435 440 445

Pro Ala Leu Asp Ser Leu Lys Pro Ala Asn Glu Asp Gln Lys Ile Gly
 450 455 460

Ile Glu Ile Ile Lys Arg Ala Leu Lys Ile Pro Ala Met Thr Ile Ala
 465 470 475 480

Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Leu Gln
 485 490 495

Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Leu Gly Asp Phe Val Asn
 500 505 510

Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala
 515 520 525

Leu Leu Asp Ala Ala Gly Val Ala Pro Leu Leu Thr Thr Ala Glu Ala
530 535 540

Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala
545 550 555 560

Met Gly Gly Met Gly Gly Gly Met Gly Gly Gly Met Phe
565 570

<210> 8

<211> 573

<212> PRT

<213> human

<400> 8

Met Leu Arg Leu Pro Thr Val Phe Arg Gln Met Arg Pro Val Ser Arg
1 5 10 15

Val Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
20 25 30

Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
35 40 45

Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
50 55 60

Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
65 70 75 80

Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
85 90 95

Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
100 105 110

Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
115 120 125

Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
130 135 140

Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
145 150 155 160

Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala

	165		170		175
Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys					
	180		185		190
Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn					
	195		200		205
Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile					
	210		215		220
Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln					
225		230		235	240
Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser					
	245		250		255
Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val					
	260		265		270
Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu					
	275		280		285
Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly					
	290		295		300
Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr					
305		310		315	320
Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp					
	325		330		335
Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys					
	340		345		350
Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu					
	355		360		365
Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu					
	370		375		380
Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly					
385		390		395	400
Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu					
	405		410		415
Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val					

	420		425		430
Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile	435		440		445
Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly	450		455		460
Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala	465		470		475
					480
Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln	485		490		495
Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn	500		505		510
Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala	515		520		525
Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Ala	530		535		540
Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala	545		550		555
					560
Met Gly Gly Met Gly Gly Gly Met Gly Gly Gly Met Phe	565		570		

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IL 99/00595

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K/08 C12N15/31 C07K16/12 A61K38/10 A61K39/04 C07K14/35		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 25744 A (RIJKSUNIVERSITEIT UTRECHT) 28 September 1995 (1995-09-28) the whole document	1-26
X	WO 96 10039 A (PEPTIDE THERAPEUTICS LIMITED) 4 April 1996 (1996-04-04) the whole document	1-26
X	US 5 780 034 A (I.R. COHEN ET AL.) 14 July 1998 (1998-07-14) the whole document	1-26
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "Z" document member of the same patent family		
Date of the actual completion of the international search 15 March 2000		Date of mailing of the international search report 29/03/2000
Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentstein 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-3040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Marie, A

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/IL 99/00595

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S.M. ANDERTON ET AL.: "Differential mycobacterial 65kDa heat shock protein T cell epitope recognition after AA-inducing or protective immunization protocols" JOURNAL OF IMMUNOLOGY, vol. 152, 1994, pages 3656-3664, XP002118234 the whole document ---	1-26
X	S.M. ANDERTON ET AL.: "Activation of T cells recognizing self 60kD HSP can protect against experimental arthritis" J. EXP. MED., vol. 181, 1995, pages 934-952, XP000881729 the whole document ---	1-26
X	B.J. PRACKEN ET AL.: "Peptide-induced nasal tolerance for a mycobacterial HSP60 T cell epitope in rats suppresses both AA and non microbially induced experimental arthritis" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 94, 1997, pages 3284-3289, XP000882776 the whole document ---	1-26
X	X.D. YANG ET AL.: "Prevention of adjuvant arthritis in rats by a nonapeptide from the 65 kD mycobacterial HSP" CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 189-194, XP000881676 the whole document ---	1-26
X	X.D. YANG ET AL.: "Treatment of AA in rats: vaccination potential of a synthetic nonapeptide from the 65 kD HSP of mycobacteria" JOURNAL OF AUTOIMMUNITY, vol. 3, 1990, pages 11-23, XP000881734 the whole document ---	1-26
X	N. LOPEZ.MORTALLA ET AL.: "A common structural motif in immunopotentiating peptides with sequences present in human autoantigens. Elicitation of a response mediated by monocytes and Th1 cells" BIOCHEMICA BIOPHYSICA ACTA, vol. 1317, 1996, pages 183-191, XP000198715 the whole document ---	1-26

-/-

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/IL 99/00595

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B. PRAKKEN ET AL.: "Nasal administration of arthritis-related T cell epitopes of HSP60 as a promising way for immunotherapy in chronic arthritis" BIOTHERAPY, vol. 10, 1998, pages 205-211, XP000881736 the whole document	1-26

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Appl. No.
PCT/IL 99/00595

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9525744 A	28-09-1995	AU 699007 B	19-11-1998
		AU 1962895 A	09-10-1995
		CA 2185826 A	28-09-1995
		EP 0751957 A	08-01-1997
		JP 9511239 T	11-11-1997
WO 9610039 A	04-04-1996	AU 3571095 A	19-04-1996
		CA 2200338 A	04-04-1996
		EP 0804475 A	05-11-1997
		JP 10509136 T	08-09-1998
US 5780034 A	14-07-1998	US 5114844 A	19-05-1992
		US 5578303 A	26-11-1996
		AT 174689 T	15-01-1999
		AU 639456 B	29-07-1993
		AU 5546790 A	09-10-1990
		CA 2029861 A	15-09-1990
		DE 69032833 D	28-01-1999
		DE 69032833 T	12-05-1999
		EP 0417271 A	20-03-1991
		FI 103976 B	29-10-1999
		FI 961398 A	27-03-1996
		JP 4502920 T	28-05-1992
		NO 300594 B	23-06-1997
		NO 964483 A	22-10-1996
		US 5671848 A	30-09-1997
		WO 9010449 A	20-09-1992